The phrase 'stem cells' is too broad to be useful on its own. Patients need the product class, source, route, evidence base, and manufacturing context, not a category word doing marketing work.
Stem cell can refer to autologous blood-forming stem cells used in established transplant medicine, embryonic stem-cell-derived products in tightly supervised trials, induced pluripotent stem-cell therapies, mesenchymal stromal cell products, and direct-to-consumer offers that borrow the language without borrowing the controls.
The patient question is never 'Is this stem cells?' It is 'What exact product is this, who made it, why this route, and what human evidence exists for my condition?'
If the product is only described as 'stem cells,' then supply chain, viability, contamination risk, and evidentiary fit remain hidden. The category word is doing the work of a smokescreen.